Denali Therapeutics Inc

-4.35 (-7.13%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.86B
Current PE96.41
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$31.62 Million
Adjusted EPS-$0.32
See more estimates
10-Day MA$61.17
50-Day MA$71.15
200-Day MA$48.15
See more pivots

Denali Therapeutics, Inc. Stock, NASDAQ:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080
United States of America
Phone: +1.615.866.8548
Number of Employees: 261


Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.